The Vita Coco Company Inc vs Charles River Laboratories Intl. Inc — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.6× The Vita Coco Company Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| COCO | CRL | |
|---|---|---|
Market Cap | $4.23B | $11.14B |
Sector | Technology | Health |
52-Week High | $84.02 | $233.60 |
52-Week Low | $32.30 | $145.57 |
Enterprise Value | $4.04B | $14.00B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →